These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 18923363)
21. The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies. Richards KA; Smith ND; Steinberg GD J Urol; 2014 Jun; 191(6):1655-64. PubMed ID: 24518761 [TBL] [Abstract][Full Text] [Related]
22. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Divrik RT; Sahin AF; Yildirim U; Altok M; Zorlu F Eur Urol; 2010 Aug; 58(2):185-90. PubMed ID: 20303646 [TBL] [Abstract][Full Text] [Related]
23. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy. Mitra AP; Alemozaffar M; Harris BN; Schuckman AK; Skinner EC; Daneshmand S Urology; 2014 Dec; 84(6):1420-6. PubMed ID: 25306479 [TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of En Bloc Transurethral Resection With 1.9 µm Vela Laser for Treatment of Non-Muscle-invasive Bladder Cancer. Xu H; Ma J; Chen Z; Yang J; Yuan H; Wang T; Liu J; Yang W; Ye Z Urology; 2018 Mar; 113():246-250. PubMed ID: 29198850 [TBL] [Abstract][Full Text] [Related]
25. The management of superficial bladder cancer. Dalbagni G Nat Clin Pract Urol; 2007 May; 4(5):254-60. PubMed ID: 17483810 [TBL] [Abstract][Full Text] [Related]
26. Outcome of Muscle-Invasive Urothelial Bladder Cancer After Radical Cystectomy. Salama A; Abdelmaksoud AM; Shawki A; Abdelbary A; Aboulkassem H Clin Genitourin Cancer; 2016 Feb; 14(1):e43-7. PubMed ID: 26363827 [TBL] [Abstract][Full Text] [Related]
27. [Analysis of 34 cases of infiltrating carcinoma of the bladder treated exclusively with partial cystectomy (part 1)]. Escudero Barrilero A; Fernández Fernández E; Jiménez Cidre M; Maganto Pavón E; Mayayo Dehesa T; Rodríguez Rodríguez R; Galvis San Juan F; Burgos Revilla FJ Arch Esp Urol; 1996 May; 49(4):349-64. PubMed ID: 8754191 [TBL] [Abstract][Full Text] [Related]
28. Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases. Fritsche HM; Burger M; Denzinger S; Legal W; Goebell PJ; Hartmann A J Urol; 2008 Nov; 180(5):1923-7. PubMed ID: 18801525 [TBL] [Abstract][Full Text] [Related]
30. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma. Raman JD; Sosa RE; Vaughan ED; Scherr DS Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658 [TBL] [Abstract][Full Text] [Related]
31. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855 [TBL] [Abstract][Full Text] [Related]
32. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes. Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764 [TBL] [Abstract][Full Text] [Related]
33. Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor. Lee SE; Jeong IG; Ku JH; Kwak C; Lee E; Jeong JS Urology; 2004 May; 63(5):873-7; discussion 877. PubMed ID: 15134968 [TBL] [Abstract][Full Text] [Related]
34. EFFICACY OF DIFFERENT RESECTIONS ON NON-MUSCLE-INVASIVE BLADDER CANCER AND ANALYSIS OF THE OPTIMAL SURGICAL METHOD. Chen GF; Shi TP; Wang BJ; Wang XY; Zang Q J Biol Regul Homeost Agents; 2015; 29(2):465-70. PubMed ID: 26122238 [TBL] [Abstract][Full Text] [Related]
35. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. Solsona E; Iborra I; Rubio J; Casanova J; Almenar S BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101 [TBL] [Abstract][Full Text] [Related]
36. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. Sonpavde G; Khan MM; Lerner SP; Svatek RS; Novara G; Karakiewicz PI; Skinner E; Tilki D; Kassouf W; Fradet Y; Dinney CP; Fritsche HM; Izawa JI; Bastian PJ; Ficarra V; Schoenberg M; Sagalowsky AI; Lotan Y; Shariat SF J Urol; 2011 Feb; 185(2):456-61. PubMed ID: 21167527 [TBL] [Abstract][Full Text] [Related]
37. [Partial cystectomy versus TUR in T1G3 tumors]. Manca GP; Martina G; Piras P; D'Alpaos M; Scuzarella S; Andreassi F Arch Ital Urol Androl; 1996 Feb; 68(1):33-4. PubMed ID: 8664918 [TBL] [Abstract][Full Text] [Related]
38. [The importance of lymphadenectomy for muscle invasive transitional cell carcinoma of the human bladder - a review of the literature]. Alloussi SH; Huber S; Gakis G; Stenzl A; Schwentner C Aktuelle Urol; 2011 Mar; 42(2):115-21. PubMed ID: 21437835 [TBL] [Abstract][Full Text] [Related]
39. Carcinoma in a bladder diverticulum: presentation and treatment outcome. Golijanin D; Yossepowitch O; Beck SD; Sogani P; Dalbagni G J Urol; 2003 Nov; 170(5):1761-4. PubMed ID: 14532771 [TBL] [Abstract][Full Text] [Related]
40. Urethrectomy following cystectomy for bladder cancer in men: practice patterns and impact on survival. Nelles JL; Konety BR; Saigal C; Pace J; Lai J; J Urol; 2008 Nov; 180(5):1933-6; discussion 1936-7. PubMed ID: 18801516 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]